Trial Profile
A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Alteminostat (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Chong Kun Dang
- 06 Feb 2020 Planned End Date changed from 1 Jun 2021 to 1 Nov 2022.
- 06 Feb 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Apr 2021.
- 25 Jul 2018 Planned End Date changed from 1 Aug 2019 to 1 Jun 2021.